Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.
The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Tatva Chintan Pharma Chem's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.
If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.
Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.
Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.
Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.
Tatva Chintan Pharma Chem Earnings Yield % Related Terms
Tatva Chintan Pharma Chem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹21.970 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Tatva Chintan Pharma Chem (NSE:TATVA) has a Earnings Yield % of 1.28% as of Jul. 25, 2026. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Tatva Chintan Pharma Chem and its competitors.
Is Tatva Chintan Pharma Chem's Earnings Yield % too high?
Tatva Chintan Pharma Chem's current Earnings Yield % is 1.28%. Overall, Tatva Chintan Pharma Chem has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tatva Chintan Pharma Chem's Earnings Yield % compare to LIN and SHW?
Tatva Chintan Pharma Chem's Earnings Yield % of 1.28% can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield % for a Chemicals company?
A good Earnings Yield % depends on the Chemicals industry context. However, Earnings Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield % mean?
A high Earnings Yield % can signal that a stock is expensive relative to its fundamentals. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Tatva Chintan Pharma Chem and its competitors. Tatva Chintan Pharma Chem's current Earnings Yield % is 1.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tatva Chintan Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem (NSE:TATVA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,493.31, compared to a current price of ₹1,722.40 — trading 15.3% above its estimated fair value. The current Earnings Yield % is 1.28%. Tatva Chintan Pharma Chem's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield % calculated?
Earnings Yield % is calculated from a company's financial statements. For Tatva Chintan Pharma Chem (NSE:TATVA), the current Earnings Yield % is 1.28% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tatva Chintan Pharma Chem (NSE:TATVA) Overvalued in 2026?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem stock appears to be overvalued.
The current stock price of ₹1,722.40 is trading 15.3% above its estimated GF Value™ of ₹1,493.31.
GuruFocus considers Tatva Chintan Pharma Chem to be Modestly Overvalued.
Key valuation signals for NSE:TATVA:
Earnings Yield %: 1.28%
GF Value™: ₹1,493.31 vs. price of ₹1,722.40 (15.3% above fair value)
No single metric tells the full story. See the NSE:TATVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
82GF Score
Get the complete analysis for NSE:TATVA
Earnings Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TATVA has been successfully added to your 
